Screener
Agios Pharmaceuticals AGIO Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Income taxes payable | — | (871) |
| Operating lease liabilities | (9,036) | (8,228) |
| Other non-current liabilities | 150 | (779) |
| Net cash used in operating activities | (176,232) | (188,613) |
| Investing activities | ||
| Purchases of marketable securities | (299,753) | (305,700) |
| Proceeds from maturities and sales of marketable securities | 508,256 | 508,894 |
| Payments associated with license agreement | (25,000) | (10,000) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's operating cash flow?
- Agios Pharmaceuticals (AGIO) reported operating cash flow of -$57.31M in Q2 2026.
- How has Agios Pharmaceuticals's operating cash flow changed year-over-year?
- Agios Pharmaceuticals's operating cash flow increased by 25.7% year-over-year, from -$77.12M to -$57.31M.
- What is the long-term trend for Agios Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's operating cash flow has grown at a -2.2% compound annual growth rate (CAGR), from -$407.32M to -$372.98M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Agios Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude